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ABSTRACT  1 
Background: There is a growing number of mHealth tools for breast cancer patients but a lack of 2 
scientific evidence for their effects. Recent studies have shown a mix of positive and negative 3 
impacts on users. Here we will assess the impact of OWise Breast Cancer, a mobile application for 4 
self-monitoring symptoms and managing care, on the process of self-management.  5 
Methods: This randomised controlled trial with early-stage breast cancer patients will assess the 6 
effect of OWise use on patient activation at 3 months from diagnosis measured by the PAM-13 7 
questionnaire. We will also assess differences in changes in health-related quality of life, 8 
psychological distress, health status and NHS health resource utilisation over the first year from 9 
diagnosis. Participants will be randomly allocated (1:1) to standard care or standard care plus OWise. 10 
Participants will complete questionnaires before starting anti-cancer treatment and at 3 months, 6 11 
months and 12 months from diagnosis. Clinical and patient-reported outcome data will be linked to 12 
health resource utilisation data from Discover, an integrated care record of primary, secondary and 13 
social care in North West London. We will measure contamination in the control group and adjust 14 
the sample size to mitigate the dilution of effect estimates. A per protocol analysis will be conducted 15 
as a sensitivity analysis to assess robustness of the primary results.  16 
Discussion: This study aims to generate evidence for the effectiveness of OWise at improving patient 17 
activation for women with early-stage breast cancer. The results will show the impact of using the 18 
tool at the patient level and the NHS health system level. The outcomes of the study will have 19 
implications for the application of OWise across the NHS for breast cancer patients and expansion 20 
into other tumour types. Assessing publicly available mHealth tools poses a challenge to trialists due 21 
to the risk of contamination. Here we apply various methods to measure, mitigate and assess the 22 
effects of contamination.  23 
Trial registration: The study was registered at clincaltrials.gov (NCT03866655) on 7 March 2019. 24 
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BACKGROUND 1 
Breast cancer is the most common form of cancer diagnosed in the United Kingdom (UK), with 2 
around 55,200 new cases each year [1]. In 2010, the National Health Service (NHS) in England spent 3 
around £675 million for the care of patients with breast cancer, with current NHS and broader 4 
societal costs likely exceeding this value [2]. With the incidence of breast cancer expected to 5 
increase in the UK over the next 15 years [1], the NHS is promoting increased self-management of 6 
care [3]. 7 
Patients and providers are looking to mHealth applications for potential self-management benefit in 8 
cancer populations [4]. mHealth is the application of mobile technology by patients or health care 9 
providers to monitor health and improve outcomes [5]. A recent review has found 12 studies 10 
assessing mHealth tools to support self-management in breast cancer patients [6]. Many of the 11 
studies assessing mHealth tools found promising results with a wound monitoring application 12 
reducing health resource utilisation [7], an electronic daily journal stabilizing daily functional activity 13 
[8] and an application providing information and support improving self-efficacy and quality of life 14 
and reducing symptom interference [9]. However, one application providing tailored information 15 
before surgery increased levels of anxiety and depression in patients [10]. The inconsistency in 16 
effects highlights the need to rigorously assess the impact of mHealth tools before encouraging use.  17 
OWise Breast Cancer is a new mhealth technology for the self-management of care in breast cancer 18 
patients. OWise provides tailored medical information, a tracker to self-monitor symptoms and 19 
functions to manage care including an appointment calendar, modifiable question list and 20 
consultation recording device [11]. OWise, listed in the NHS Apps Library, is freely available for 21 
download [12]. OWise was developed outside an academic setting but followed the mHealth 22 
development and evaluation process defined by Whittaker et al [13]. Programmers designed the 23 
tool in an iterative process with patients and conducted thorough user testing.  24 
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A qualitative study evaluating OWise in the Netherlands showed patients and providers found the 1 
tool usable and felt it had the potential to help patients take in more information from 2 
consultations, manage appointments and feel more in control during treatment [14]. To understand 3 
the impact of OWise on health behaviours, health-related quality of life (HRQoL) and NHS resource 4 
utilisation, comparative data is needed.  5 
Conceptual model 6 
The conceptual model for OWise is based on the Individual and Family Self-Management Theory. 7 
This theory posits that self-management is the process by which individual and family health 8 
knowledge and behaviours are used to reach certain health outcomes (Figure 1) [15]. The theory 9 
takes into account individual, medical, social and environmental factors that influence the process of 10 
self-management.  11 
OWise aims to improve HRQoL and reduce health resource utilisation by intervening on the self-12 
management process. The digital tool aims to increase knowledge and beliefs by providing tailored 13 
medical information and recommended questions in the modifiable question list. OWise aims to 14 
improve self-regulation skills and abilities with the symptom tracker and appointment calendar. The 15 
proximal outcome we will measure is patient activation and distal outcomes are HRQoL, 16 
psychological distress, health status and health care costs. Studies have previously linked patients 17 
activation to better HRQoL, improved care experiences and lower use of NHS resources [16–18].  18 
STUDY DESIGN 19 
Aim 20 
This study aims to understand the impact of OWise on health behaviours, HRQoL and health care 21 
utilisation in early-stage breast cancer patients compared to standard care alone.  22 
Study design  23 
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We will evaluate the effectiveness of OWise using a multi-centre, individually randomized, parallel 1 
controlled trial recruiting 122 patients. The intervention group will receive OWise plus standard care, 2 
while the control group will receive standard care alone to assess superiority. Due to the nature of 3 
the digital tool, it is not possible to blind participants or providers. Outcomes are reported directly 4 
by participants and analysis depends on the randomly assigned group. Therefore, outcome assessors 5 
and data analysts are not blinded either. Patients in both groups will complete patient-reported 6 
outcome measures (PROMs) to assess outcomes at baseline, 3 months, 6 months and 12 months 7 
from diagnosis. See Figure 2 for the SPIRIT diagram showing the schedule of enrolment and 8 
assessment and Additional File 1 for the SPIRIT-PRO checklist.  9 
Randomisation 10 
Patients will be randomly assigned (1:1) to the intervention or control group [19,20]. Randomisation 11 
will be stratified by age group and centre. Age is grouped by (1) under 60 years old and (2) 60 years 12 
old and over as internet access drops between age groups 45-55 and 55-65 [21] and the incidence of 13 
breast cancer in the UK is evenly distributed around age 60 [1]. The Institute of Cancer Research 14 
Clinical Trials and Statistics Unit Randomisation Service will generate the randomisation sequence 15 
and allocate the group by phone. 16 
Participants 17 
Females (aged 18 years or over) newly diagnosed with early-stage breast cancer as a first primary 18 
diagnosis will be eligible to take part. Eligibility was restricted to early-stage and first primary 19 
diagnoses as metastatic patients may have confounding care and psychosocial experiences and 20 
patient activation naturally increases with time after a breast cancer diagnosis [22]. Patients must 21 
complete the baseline measure before starting anti-cancer treatment. All participating sites are 22 
located in the UK, a list of which can be found on the registration website. Exclusion criteria include 23 
private care, difficulty reading in English, significant cognitive impairments or poor mental health 24 
and no internet access.  25 
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Intervention Group 1 
OWise is an mHealth tool accessible online or by mobile application [11]. The tool offers tailored 2 
medical information, a modifiable question list with tailored recommended questions, a medical 3 
terms glossary, useful links to local resources, a tracking tool for symptoms, an appointment 4 
calendar and a consultation recording device.  5 
In the study, only patients randomised into the intervention group will receive information about 6 
OWise. The individual enrolling the patient will provide instructions for creating an account and 7 
navigating the tool. Participants will be free to use the tool as much as they wish to mimic real-world 8 
use of the application. The tool is free to download and accessible to the participant beyond the 9 
study period. 10 
Control Group 11 
Participants in the control group will receive all standard information including leaflets and links to 12 
resources that patients usually receive at the time of a new breast cancer diagnosis. Participants in 13 
the control group will not be given information about the tool but will also not be explicitly 14 
prohibited from using the tool.  15 
Primary objective 16 
The primary objective of this study is to test whether use of OWise increases patient activation 17 
scores at three months follow-up by at least four points more than standard care. 18 
Secondary objectives 19 
(1) To test whether any difference in the change in patient activation between the two groups still 20 
exists after controlling for potential covariates. 21 
(2) To test whether the use of OWise leads to a smaller decrease in health status at three months 22 
follow-up than standard care after controlling for potential covariates. 23 
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(3) To test whether the use of OWise leads to a smaller decrease in HRQoL at three months follow-1 
up than standard care alone after controlling for potential covariates. 2 
(4) To test whether the use of OWise leads to a lower increase in psychological distress at three 3 
months follow-up compared to standard care alone after controlling for potential covariates. 4 
(5) To test whether the use of OWise reduces the rate of resource utilisation in the first year 5 
following diagnosis compared to standard care among patients registered in Discover, an 6 
integrated health and social care record in North West London. 7 
(6) To test whether the use of OWise reduces the average cost per patient in the first year 8 
following diagnosis compared to standard care among patients registered in Discover.  9 
(7) To describe the change in patient activation in the intervention group compared to the control 10 
group in the first year following diagnosis. 11 
(8) To describe the level of OWise uptake in the intervention group in the first year following 12 
diagnosis. 13 
(9) To describe the change in the pattern of patient activation, HRQoL, psychological distress and 14 
health status in the intervention group compared to the control group in the first year following 15 
diagnosis. 16 
Procedure 17 
Recruitment 18 
We will continuously sample all patients meeting eligibility criteria diagnosed within the recruitment 19 
period. A member of the clinical team will identify eligible patients in multi-disciplinary team 20 
meetings or clinic lists and invite potential participants at diagnosis. The name of the digital tool will 21 
not be disclosed when inviting patients. If a patient shows interest, a researcher will provide further 22 
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information either in-person or over the phone. Patients can decide to take part any time before 1 
starting anti-cancer treatment. 2 
After meeting eligibility criteria and providing written informed consent, participants will be 3 
randomised. The researcher will inform the participant of their allocation and provide instructions 4 
for accessing the online PROM collection tool. Participants in the intervention arm will be required 5 
to complete the baseline measure before using OWise.  6 
Measures 7 
Primary outcome measure 8 
Patient Activation Measure (PAM-13) 9 
Patient activation describes the knowledge, skills and confidence a person has in managing their 10 
health and care [23,24]. The PAM-13 is a 13-item questionnaire that measures patient activation 11 
[25]. Each item has four response options from (1) ‘strongly disagree’ to (4) ‘strongly agree,’ and ‘not 12 
applicable.’ PAM-13 scores will be calculated according to the guidelines [25]. Scores range on a 13 
scale of 1-100 corresponding to four activation levels: 1 (≤47.0) not believing activation important, 2 14 
(47.1-55.1) a lack of knowledge and confidence to take action, 3 (55.2-67.0) beginning to take action 15 
and 4 (≥67.1) taking action [25]. This measure has been used widely among cancer patients and 16 
across the UK [26–28] and has robust evidence of reliability and validity [23,29,30]. Patient 17 
activation, as measured by the PAM-13, can be targeted by interventions and change over time [24]. 18 
Previous work has shown that higher patient activation is associated with HRQoL and lower health 19 
care utilisation [16–18,31]. 20 
Secondary outcome measures 21 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core30 22 
(EORTC-QLQ-C30 version 3) and Updated Quality of Life Breast Cancer Module (QLQ-BR45)  23 
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This 30-item instrument measuring HRQoL has five functional scales (physical, role, cognitive, 1 
emotional and social), a global quality of life scale, eight symptom scales or items (fatigue, pain, 2 
nausea and vomiting, dyspnoea, loss of appetite, sleep disturbance, constipation and diarrhoea) and 3 
a single item assessing perceived financial impact [32]. The QLQ-BR45 contains five functional scales 4 
or items (body image, future perspective, sexual functioning, sexual enjoyment and breast 5 
satisfaction) and 7 symptom scales or items (systemic therapy side effects, upset by hair loss, arm 6 
symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms and endocrine 7 
sexual symptoms) [33]. Scores will be calculated according to EORTC guidelines [34]. All scores range 8 
from 0-100. Higher scores on functional scales and global quality of life indicate better function and 9 
HRQoL, respectively. Higher scores on symptom scales and items indicate higher symptom burden 10 
[35]. The measures have strong evidence of validity and reliability in early-breast cancer patients and 11 
have been used in a number of clinical trials allowing for comparisons [33,36]. 12 
Hospital Anxiety and Depression Scale (HADS) 13 
This 14-item questionnaire measures psychological distress, with seven items assessing anxiety and 14 
seven items assessing depression with the summed total score reflecting the level of psychological 15 
distress [37]. Three continuous scales will be calculated (anxiety, depression and overall 16 
psychological distress) according to HADS guidelines [37,38]. Higher scores indicate more 17 
psychological distress [37,38]. The HADS has evidence of reliability and validity in early breast cancer 18 
patients [36,39]. 19 
EuroQol 5-Dimension 5-Level (EQ-5D-5L) 20 
This instrument assessing health status consists of five items and a visual analogue scale [40]. The 21 
items cover five dimensions (mobility, self-care, usual activities, pain/discomfort and 22 
anxiety/depression). Each dimension has five response levels from ‘no problems’ to ‘extreme 23 
problems.’ The visual analogue scale records the patient’s self-rated health from 0-100, with the 24 
highest score indicating ‘The best health you can imagine’ and the lowest score indicating ’The worst 25 
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health you can imagine.’ Responses to each item combine to form a five-digit number that describes 1 
the patient’s health state. A corresponding index value will be assigned according to a recent 2 
valuation study conducted in England [41]. The EQ-5D-5L has a large base of evidence and for 3 
validity and reliability in breast cancer patients and can also be used to conduct economic analysis 4 
[42]. 5 
Health Care Utilisation 6 
Health care utilisation will be assessed using data routinely collected in Discover. The Discover linked 7 
dataset includes coded information on health and social care resource utilisation of individuals 8 
registered with a GP practice in the North West London region. Information is collected about the 9 
number and type of appointments from primary, secondary and social care for each patient between 10 
diagnosis and one year follow-up. 11 
Health Care Costs 12 
The Discover linked dataset also provides the current costs of health and social care to Clinical 13 
Commissioners in North West London based upon Commissioner local  pricing. Information on the 14 
cost of each type of appointment is calculated routinely and collated together across health care 15 
settings to provide a measure of health and social care utilisation of each patient. 16 
OWise Uptake 17 
With patient informed consent, we will evaluate OWise uptake by reviewing timestamps that 18 
indicate logging in or modification of a specific function. This information will allow us to evaluate 19 
whether participants use the tool, which function patients use and how long the tool is used for. 20 
Contamination  21 
Patient responses to items at each measurement time point will indicate contamination . A set of 19 22 
items will ask participants to identify the use of supportive care services including self-management 23 
mobile phone applications or websites. If a participant says yes, we will ask them to name the source 24 
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in a free-text box to determine whether or not OWise has been used. Prior to recruitment close, the 1 
statistician will assess the level of contamination and increase the sample size commensurately [43].  2 
Data management 3 
The study steering committee determined a data monitoring committee was unnecessary for this 4 
study as it poses a minimal risk to patient safety and uses only routinely collected or patient-5 
reported data.  6 
Patient-Reported Outcome Measure Data 7 
Participants will complete PROMS using PROFILES (Patient Reported Outcomes Following Initial 8 
treatment and Long term Evaluation of Survivorship), an online PROM collection and data 9 
management system developed in the Netherlands and implemented at the Royal Marsden [44]. 10 
Follow-up time points will be managed by the Royal Marsden as the coordinating centre. PROM 11 
responses cannot be viewed by the researcher or clinical team until extracted at the end of the study 12 
when it will be linked to other study data by the study identification number. 13 
Clinical Data 14 
With patient informed consent, researchers will collect relevant clinical data from the local 15 
electronic patient record and store it digitally at the Royal Marsden. Clinical data will be extracted at 16 
the end of the study and linked to other study data by the study identification number.  17 
Health care utilisation 18 
Study participants will be identified in Discover by NHS number and flagged with the study 19 
identification number. The Imperial College Health Partners Discover team, will access a de-20 
identified version of the data to analyse health and social care resource utilisation on behalf of the 21 
Royal Marsden. Health and Social Care resource utilisation data will be extracted at the end of the 22 
study and linked to other study data by the study identification number. 23 
OWise Engagement 24 
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Participants will be provided with a unique invitation code linked to their study identification 1 
number to input when creating an OWise account. Timestamp data will be identified by the 2 
invitation code and extracted at the end of the study. The data will be linked to other study data by 3 
the unique invitation code.  4 
Sample size 5 
Sample size calculations are based on the change in PAM-13 score from baseline to three months. A 6 
difference of four points is considered clinically relevant [29,45]. In a similar study, the mean PAM-7 
13 score at baseline for the intervention group was 61.3 (SD 16.61) and 67.9 (SD 16.85) at three 8 
months [46]. For the control group, the study reported a mean PAM-13 score at baseline of 62.1 (SD 9 
17.30) and 62.8 (SD 14.94) at three months. Based on these findings, this study is planned to detect 10 
a mean change difference of 5.90 assuming a common standard deviation of 10.0. Using an 80% 11 
power the study will recruit 47 patients per group. This was calculated using a 2-sided test with 12 
alpha=0.05. We will increase the sample size taking 23% attrition at three months into account 13 
(47/(1-0.23)) to 61 patients per group [47] and, as mentioned above, increase the sample size 14 
accordingly if contamination is found near the end of recruitment. 15 
Analysis 16 
The CONSORT-EHEALTH recommendations for reporting randomised trials for developing and 17 
evaluating eHealth interventions will guide trial reports [48]. Primary and secondary outcomes will 18 
be assessed using intention-to-treat analysis where all participants are analysed according to the 19 
arm to which they were randomised. We will conduct a sensitivity analysis separately as described 20 
below. The data will be analysed after all patients have completed the one year follow-up. Data will 21 
be reported descriptively at each time point. Mean and standard deviation or median and range will 22 
be reported for continuous outcomes. Frequency and percentage will be reported for categorical 23 
outcomes.  24 
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The association between potential covariates and the primary and secondary endpoints will be 1 
explored using univariate analysis. Any variables with a p-value of <0.1 will be included in the 2 
multivariable model. Multivariable analysis controlling for potential covariates associated with the 3 
particular outcome will be conducted using logistic regression for binary outcomes and multiple 4 
linear regression for continuous outcomes. Two-sided p-values of <0.05 will be considered 5 
statistically significant.  6 
Primary endpoint 7 
We will compare the PAM-13 score change between the intervention arm and the control arm using 8 
independent t-test. Data will be log transfored to achieve normality as appropriate. We will also 9 
compare the mean change in PAM-13 score in the intervention and control arm in a multiple linear 10 
regression model including potential covariates.  11 
Secondary endpoints 12 
We will compare the mean change in EQ-5D-5L index score and visual analogue score,  EORTC-QLQ-13 
C30 and BR45 scale scores in the intervention and control arm in simple and multiple linear 14 
regression models including potential covariates.  15 
We will compare the mean change in the three HADS scale scores in the intervention and control 16 
arm in simple and multiple linear regression models including potential covariates. Based on the 17 
continuous overall psychological distress score, patients are classified as ‘distressed’ when they have 18 
a score of ≥8, and ‘not distressed’ when they have a score <8. Frequency, percentages and any 19 
appropriate 95% confidence intervals of this dichotomization at baseline and 3 months will be 20 
presented. Chi-square or Fisher’s exact test will be used to compare the level of distress between 21 
the intervention and control arms.   22 
We will present the mean rate of resource utilisation and cost per patient in the two groups by type 23 
of resource (primary, secondary and social care) and for total NHS resources used. Simple and 24 
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multiple linear regression models including potential covariates will compare the mean rate of total 1 
resource utilisation and the mean cost per patient in the two groups .  2 
We will describe the average scale scores of the four validated measures in the two groups at the 3 
four time points and show graphically the trend in scale scores in each group. We will also compare 4 
the mean change in scale scores of the measures across the four time points between the 5 
intervention and control arm using a mixed models approach.   6 
To describe OWise uptake, the average number of times logging in at daily intervals throughout the 7 
follow up period will be described and the trend of mean logging in over time will be graphed. We 8 
will also show the average frequency of use for each function of the tool over time. 9 
Sensitivity analysis 10 
Per protocol analysis will be performed as a sensitivity analysis to assess the impact of 11 
contamination on the primary analysis. In the sensitivity analysis, all participants in the control arm 12 
that report using OWise will be excluded. If the sensitivity analysis produces results dissimilar from 13 
the primary analysis, we will determine the primary results are not robust and further research is 14 
required. 15 
Missing data 16 
Missing data of multi-item scales will be handled according to questionnaire guidelines. Where 17 
guidelines are unavailable, items will be mean-imputed if at least half of the items from the scale are 18 
answered. Descriptive statistics are based on complete case analysis. We will analyse available data 19 
before imputation for the groups comparison and use the complete case data as a form of sensitivity 20 
analysis.  21 
Dissemination 22 
Any protocol modifications will be submitted for approval to the research ethics committee, 23 
reflected in the online registration and disseminated by email to site principal investigators and trial 24 
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coordinators. To mitigate attrition, the coordinating centre will engage participants with newsletters 1 
via email or post. These will also discuss any changes to study procedures relevant to participants 2 
and results of the study. Each party involved will continue to own the data they collected, i.e. The 3 
Royal Marsden will own the clinical and PROM data, Discover on behalf of the NWL data custodians 4 
will own the health and social care resource utilisation data, and Px Healthcare will own the OWise 5 
uptake data. The statistician and health economists will have access to the final linked trial dataset. 6 
There are no plans to provide public access to the full protocol, participant-level data or statistical 7 
code. The researchers aim to publish results in a peer-reviewed journal and share via social media 8 
and conferences. Authorship will be determined by the owner of the data included in the 9 
publication.  10 
DISCUSSION 11 
This study aims to evaluate the impact of OWise on patient activation, psychosocial outcomes and 12 
health and social care utilisation. In the face of an expanding mHealth field, robust, comparative 13 
studies are vital to understand the impact of such tools on patients.  14 
Evaluating mHealth technology available to the public poses a challenge to study design due to the 15 
high risk of contamination. To mitigate contamination, we will not disclose the specific tool to 16 
participants unless randomised to the intervention group. We felt individual randomisation was 17 
appropriate over cluster randomisation as health care providers are not directly involved in the 18 
administration of the intervention and OWise use in the UK is low [43]. Specific items in the 19 
questionnaires will measure contamination at each time point. The items will ask patients to identify 20 
any supportive care tools or information sources used, including websites and mobile phone 21 
applications, with free-text boxes.  22 
Previous work suggests adjusting the sample size for expected contamination [43]. However, no 23 
previous literature has reported contamination levels in similar studies. We decided instead to 24 
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assess the level of contamination before the end of recruitment and increase the sample size if 1 
necessary. To assess the impact of contamination on effect estimates, we will also conduct a 2 
sensitivity analysis using per-protocol analysis [49]. This will test the robustness of our primary 3 
intention-to-treat analysis, the gold standard method for randomised controlled trials [50].  4 
This study will use a new web-based PROM collection tool implemented by the Royal Marsden called 5 
PROFILES [44]. Electronic capture of PROMS provides a number of benefits including flexibility for 6 
participants, more accurate and timely data collection and reduced time and costs to conduct 7 
research [51]. There is also growing evidence for equivalence between paper and electronic PROM 8 
collection [52]. 9 
This study design may be limited by relying on patient-reports of OWise use to measure 10 
contamination, However, this is unavoidable due to data protection arrangements of the tool. 11 
Participants may also use similar mHealth tools which could confound the results. The open-ended 12 
items assessing contamination will measure the use of other tools and enable us to control for these 13 
effects in analysis as much as possible. This study will also be limited by updates of the application. 14 
Post-hoc analysis of differences before and after the updates will allow us to assess whether and 15 
changes in the application reduce or enlarge any effects or change participant uptake.  16 
This study will allow us to assess whether OWise, a patient-focused mHealth technology, can have 17 
an impact on self-management processes, HRQoL and NHS health resource utilisation. With the 18 
comparative nature of the study and conduct in the NHS system, this will have broad implications for 19 
the adoption of this tool by the NHS in future. If successful, this application can be modified to meet 20 
the needs of other tumour groups. This study is also applying new methods in a growing field of 21 
mHealth evaluation and can serve as an example for researchers in future. 22 
TRIAL STATUS  23 
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Protocol version 2.0 31/05/2019 was approved on 11/07/2019 with recruitment pending. End of 1 
recruitment is planned for 30 June 2020.  2 
LIST OF ABBREVIATIONS 3 
UK United Kingdom 4 
NHS National Health Service 5 
PROM Patient-reported Outcome Measure 6 
HRQoL Health-Related Quality of Life 7 
EORTC-QLQ-C30 European Organisation for the Research and Treatment of Cancer – Quality of Life 8 
Questionnaire – Core 30 9 
BR-45 Breast Cancer 45 10 
EQ-5D-5L EuroQol 5-Dimension 5-Level 11 
HADS Hospital Anxiety and Depression Scale 12 
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Figure 2.  Schedule of enrolment and assessments. 1 
 2 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
TIMEPOINT -t1 0 
3 months from 
diagnosis 
6 months from 
diagnosis 
12 months from 
diagnosis 
ENROLMENT:      
Eligibility screen X     
Informed consent  X     
Allocation  X    
INTERVENTIONS:      
Provision of OWise  X    
ASSESSMENTS:      
Demographics X X    
PAM-13  X X X X 
EORTC-QLQ-C30  X X X X 
EORTC-QLQ-BR45  X X X X 
HADS  X X X X 
EQ-5D-5L  X X X X 
Clinical diagnosis  X    
Treatment and 
hospitalisation data 
    X 
Discover data     X 
OWise use data     X 
 3 
